lopinavir/ritonavir plus interferon ß-1a for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Ader (lopinavir/ritonavir plus interferon) NCT04315948		RCT	lopinavir/ritonavir plus interferon ß-1a	standard of care	COVID 19 hospitalized	some concern	145/148	safety concern	statistically significant 30 % decrease in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias statistically significant 86 % increase in serious adverse events with a moderate degree of certainty due to some concern in risk of bias statistically significant 3.4-fold increase in arrhythmia with a moderate degree of certainty due to some concern in risk of bias statistically significant 5.6-fold increase in elevated liver enzymes with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis